<DOC>
	<DOCNO>NCT02996110</DOCNO>
	<brief_summary>The purpose study determine whether nivolumab combination therapy effective nivolumab combination ipilimumab treat patients/subjects advance renal cell carcinoma .</brief_summary>
	<brief_title>A Study Test Combination Treatments People With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Advanced Renal Cell Carcinoma Must least 1 lesion measurable disease Life expectancy least 3 month Patients/subjects suspect known central nervous system metastases unless adequately treat Patients/subjects autoimmune disease Patients/subjects need daily oxygen therapy Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>